Literature DB >> 33276655

Commensal Bacterium Rothia aeria Degrades and Detoxifies Gluten via a Highly Effective Subtilisin Enzyme.

Guoxian Wei1, Ghassan Darwish1, Frank G Oppenheim1, Detlef Schuppan2,3, Eva J Helmerhorst1.   

Abstract

Celiac disease is characterized by a chronic immune-mediated inflammation of the small intestine, triggered by gluten contained in wheat, barley, and rye. Rothia aeria, a gram-positive natural colonizer of the oral cavity and the upper digestive tract is able to degrade and detoxify gluten in vitro. The objective of this study was to assess gluten-degrading activity of live and dead R. aeria bacteria in vitro, and to isolate the R. aeria gluten-degrading enzyme.
METHODS: After an overnight fast, Balb/c mouse were fed a 1 g pellet of standard chow containing 50% wheat (and 4% gliadin) with or without 1.6 × 107 live R. aeria bacteria. After 2 h, in vivo gluten degradation was assessed in gastric contents by SDS-PAGE and immunoblotting, and immunogenic epitope neutralization was assessed with the R5 gliadin ELISA assay. R. aeria enzyme isolation and identification was accomplished by separating proteins in the bacterial cell homogenate by C18 chromatography followed by gliadin zymography and mass spectrometric analysis of excised bands.
RESULTS: In mice fed with R. aeria, gliadins and immunogenic epitopes were reduced by 20% and 33%, respectively, as compared to gluten digested in control mice. Killing of R. aeria bacteria in ethanol did not abolish enzyme activity associated with the bacteria. The gluten degrading enzyme was identified as BAV86562.1, here identified as a member of the subtilisin family.
CONCLUSION: This study shows the potential of R. aeria to be used as a first probiotic for gluten digestion in vivo, either as live or dead bacteria, or, alternatively, for using the purified R. aeria enzyme, to benefit the gluten-intolerant patient population.

Entities:  

Keywords:  Bacillus; Rothia; celiac disease; commensal; cure; degradation; detoxify; epitope; gluten; neutralize; subtilisin

Mesh:

Substances:

Year:  2020        PMID: 33276655      PMCID: PMC7761627          DOI: 10.3390/nu12123724

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  38 in total

1.  A monoclonal antibody that recognizes a potential coeliac-toxic repetitive pentapeptide epitope in gliadins.

Authors:  A A Osman; H H Uhlig; I Valdes; M Amin; E Méndez; T Mothes
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 2.566

2.  A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease.

Authors:  Carlo Catassi; Elisabetta Fabiani; Giuseppe Iacono; Cinzia D'Agate; Ruggiero Francavilla; Federico Biagi; Umberto Volta; Salvatore Accomando; Antonio Picarelli; Italo De Vitis; Giovanna Pianelli; Rosaria Gesuita; Flavia Carle; Alessandra Mandolesi; Italo Bearzi; Alessio Fasano
Journal:  Am J Clin Nutr       Date:  2007-01       Impact factor: 7.045

3.  Rothia bacteremia: a 10-year experience at Mayo Clinic, Rochester, Minnesota.

Authors:  Poornima Ramanan; Jason N Barreto; Douglas R Osmon; Pritish K Tosh
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

4.  Oral enzyme therapy for celiac sprue.

Authors:  Michael T Bethune; Chaitan Khosla
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

5.  Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease.

Authors:  C Mitea; R Havenaar; J Wouter Drijfhout; L Edens; L Dekking; F Koning
Journal:  Gut       Date:  2007-05-09       Impact factor: 23.059

6.  Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue.

Authors:  Jonathan Gass; Michael T Bethune; Matthew Siegel; Andrew Spencer; Chaitan Khosla
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

7.  Comparison of canine and human gastrointestinal physiology.

Authors:  J B Dressman
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

8.  Bacterial biogeography of the human digestive tract.

Authors:  Jennifer C Stearns; Michael D J Lynch; Dilani B Senadheera; Howard C Tenenbaum; Michael B Goldberg; Dennis G Cvitkovitch; Kenneth Croitoru; Gabriel Moreno-Hagelsieb; Josh D Neufeld
Journal:  Sci Rep       Date:  2011-11-25       Impact factor: 4.379

9.  A food-grade enzyme preparation with modest gluten detoxification properties.

Authors:  Jennifer Ehren; Belen Morón; Edith Martin; Michael T Bethune; Gary M Gray; Chaitan Khosla
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

10.  Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT.

Authors:  Parasuraman Padmanabhan; Johannes Grosse; Abu Bakar Md Ali Asad; George K Radda; Xavier Golay
Journal:  EJNMMI Res       Date:  2013-08-02       Impact factor: 3.138

View more
  1 in total

Review 1.  Salivary Microbiome in Pediatric and Adult Celiac Disease.

Authors:  Dimitri Poddighe; Almagul Kushugulova
Journal:  Front Cell Infect Microbiol       Date:  2021-02-17       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.